Tag: Exelixis

April 7, 2021

5 Top Biotechnology ETFs

For investors looking for less volatility compared to stocks, here's an overview of the five largest biotechnology ETFs for consideration.
June 22, 2020

7 Small Biotech ETFs

Want to invest in small biotech ETFs? INN profiles seven examples that life science investors may want to look into.
October 15, 2018

Biotech Update: Q3 2018 in Review

With the first three quarters of 2018 over, the Investing News Network is reviewing top news in the biotech space...
September 19, 2018

Kidney Cancer Treatment Gets Health Canada Approval

Exelixis can add a new regulatory approval for its product with Health Canada's approval of Cabometyx, a treatment for a...
September 19, 2018

Exelixis’ Partner Ipsen Announces Health Canada’s Approval of CABOMETYX (cabozantinib) Tablets for the Treatment of Adults with Previously Treated Advanced Renal Cell Carcinoma

Exelixis (NASDAQ:EXEL) today announced that its partner Ipsen Biopharmaceuticals Canada received approval from Health Canada of CABOMETYX (cabozantinib) tablets for the treatment...
September 7, 2018

Exelixis Announces New Recommendations for CABOMETYX (Cabozantinib) Tablets

Exelixis (NASDAQ:EXEL) announced that the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines to include new recommendations for CABOMETYX (cabozantinib)...
July 5, 2018

Exelixis Announces CELESTIAL Phase 3 Pivotal Trial Results Published in The New England Journal of Medicine

Exelixis (Nasdaq:EXEL) announced that The New England Journal of Medicine (NEJM) published results from the CELESTIAL phase 3 pivotal trial of cabozantinib in...